Oura’s confidential S-1 filing in May 2026, underwritten by Goldman Sachs, Morgan Stanley, and JPMorgan, has centered trader focus on its IPO valuation amid rapid scaling. The company’s October 2025 Series E raised $900 million at an $11 billion post-money valuation, supported by roughly $1 billion in 2025 revenue from over 5 million rings sold and accelerating subscription growth. Market-implied odds remain fragmented across $7.5–20 billion+ bands because public multiples for high-growth health-tech names depend on 2026 revenue trajectory, gross-margin expansion, and broader wearable-sector sentiment, while comparable late-2025 funding rounds and secondary trading activity around $52–64 per share provide only loose benchmarks. Key near-term catalysts include SEC comment resolution and any pre-IPO revenue updates that could shift consensus on whether the exit clears the prior private valuation or commands a premium.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui$7.5B–$10B 17%
$10B–$12.5B 14%
$20B+ 14%
$15B–$17.5B 13%
$185,323 Vol.
$185,323 Vol.
<$7.5B
8%
$7.5B–$10B
17%
$10B–$12.5B
14%
$12.5B–$15B
11%
$15B–$17.5B
13%
$17.5B–$20B
12%
$20B+
14%
No IPO before January 2027
8%
$7.5B–$10B 17%
$10B–$12.5B 14%
$20B+ 14%
$15B–$17.5B 13%
$185,323 Vol.
$185,323 Vol.
<$7.5B
8%
$7.5B–$10B
17%
$10B–$12.5B
14%
$12.5B–$15B
11%
$15B–$17.5B
13%
$17.5B–$20B
12%
$20B+
14%
No IPO before January 2027
8%
If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
Pasar Dibuka: May 26, 2026, 12:28 PM ET
Resolver
0x69c47De9D...If no IPO occurs by December 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before January 2027".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency. It is calculated as the number of shares outstanding multiplied by the closing share price on the first trading day.
If the relevant value falls exactly between two brackets, then this market will resolve to the higher range bracket.
Resolution will be based on the primary exchange’s official listing page. In the event that the relevant figure is not displayed, another reliable source will be used.
In the event of an interruption in the course of the normal trading session on Oura’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that as the first day of trading for purposes of this market.
Resolver
0x69c47De9D...Oura’s confidential S-1 filing in May 2026, underwritten by Goldman Sachs, Morgan Stanley, and JPMorgan, has centered trader focus on its IPO valuation amid rapid scaling. The company’s October 2025 Series E raised $900 million at an $11 billion post-money valuation, supported by roughly $1 billion in 2025 revenue from over 5 million rings sold and accelerating subscription growth. Market-implied odds remain fragmented across $7.5–20 billion+ bands because public multiples for high-growth health-tech names depend on 2026 revenue trajectory, gross-margin expansion, and broader wearable-sector sentiment, while comparable late-2025 funding rounds and secondary trading activity around $52–64 per share provide only loose benchmarks. Key near-term catalysts include SEC comment resolution and any pre-IPO revenue updates that could shift consensus on whether the exit clears the prior private valuation or commands a premium.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui


Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan